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   INTRODUCTION
INTRODUCTION
Control of airway is one of the defining moments of Anaesthesia.
Before the twentieth century, intubation of the trachea had been described and 
performed rather crudely, often using fingers as a makeshift laryngoscope without using 
any pharmacological agents. At that time the only regular intubation of the trachea that 
was taking place was in the resuscitation of asphyxiated neonate. 
In 1880, Sir William Maceven20, a Scottish surgeon was the first to perform 
endotracheal intubation.
In 1895 Kirstein became the first to perform endotracheal intubation using a 
laryngoscope.
The  credit  of  developing  the  scientific  principles  of  direct  laryngoscopy  and 
endotracheal  intubation  belongs  to  the  American  otolaryngologist  Dr.  Chevallier 
Jackson. In 1913-jackson devised a U-shaped laryngoscope.
In 1913-Janeway introduced L-shaped laryngoscope with batteries in the handle.
Now we use rigid direct laryngoscopes to view the larynx and adjacent structures 
under direct vision for the purpose of endotracheal intubation. This causes direct trauma 
to the oropharynx and larynx and apart from this it also causes sympathetic stimulation 
resulting in rise in heart rate, systolic blood pressure, diastolic blood pressure and mean 
arterial pressure.
Although the haemodynamic stress response is transient, and of little consequence 
in healthy individuals,  it  is hazardous to those with systemic hypertension,  coronary 
artery disease, and cerebro vascular disease. Complications like myocardial ischaemia, 
infarction, left ventricular failure, arrhythmias, intracranial hemorrhage can occur due to 
this response.
The major cause of the haemodynamic stress response is due to the stimulation of 
supraglottic  area  by  the  laryngoscope  blade  followed  by  additional  stimulation 
contributed by tracheal tube placement.
Till date the mainstay of attenuation of the haemodynamic stress response was 
done  by  using  various  drugs  like  local  anesthetics,  beta-blockers,  calcium  channel 
blockers, opiods and vasodilators.
All of these techniques which are suggested have some disadvantages related to 
either cardiovascular or respiratory depression, but none of them directly inhibits the 
release of  catecholamines.  Magnesium sulphate  blocks the release of catecholamines 
from the adrenergic nerve terminals and adrenal glands.
The role of magnesium starts as back as the 17th century and covers a large span 
of the chemical and pharmacological fields of knowledge.
Until recently the function of Magnesium in biological processes was largely 
ignored to the point where it was described as the “forgotten ion”. Magnesium is the 
fourth most abundant cation in the body and the second abundant intracellular cation. 
It is involved in several processes like control of vasomotor tone, cardiac excitability 
and neuro transmitter release. In many of its actions it is likened to a physiological 
calcium antagonist.
In  our  study,  which  was  carried out  in  the Department  of  Anaesthesiology at 
Thanjavur medical college hospital we compared intravenous Magnesium sulphate and 
Lignocaine in the attenuating haemodynamic stress response (increase in heart rate and 
an increase in the mean arterial pressure) to laryngoscopy and intubation, and find out 
which drug is better.

                  AIM
AIM
This study was done with the following intentions:
 To compare the efficacy of Magnesium sulphate over Lignocaine in attenuating 
the cardiovascular responses to 
 Laryngoscopy and 
 Intubation.
 To observe any adverse effects of Magnesium sulphate in the specified dosage.
 To observe any prolongation of neuromuscular blockade in this specified dose.
ANATOMY     & 
NERVE SUPPLY 
OF LARNYX
ANATOMY OF LARYNX
ANATOMY OF VOCAL CORDS
ANATOMY AND NERVE SUPPLY OF THE UPPER 
AIRWAY14
The pharynx is a U shaped fibromuscular structure that extends from the base of 
the skull to the cricoid cartilage. It opens anteriorly into the nasal cavity, mouth and the 
larynx, which conveniently divides the pharynx into three parts termed as nasopharynx, 
oropharynx and laryngopharynx respectively. At the base of the tongue, the epiglottis 
functionally separate the oropharynx from the laryngopharynx. 
Sensory  nerve  supply  of  the  upper  airway  is  derived  from the  cranial  nerves 
trigeminal, glossopharyngeal and the vagus.
The palatine nerve provides sensory fibers from trigeminal nerve to hard and soft 
palate.  The lingual nerve provides general sensation to the anterior two thirds of the 
tongue,  and  the  glossopharyngeal  nerve  to  the  posterior  one  third  of  the  tongue. 
Branches of the facial nerve and the glossopharyngeal nerve provide sensation of taste to 
anterior two thirds and posterior one third respectively.
The glossopharyngeal nerve also innervates the roof of the pharynx, the tonsils 
and the undersurface of the soft palate. The pharyngeal surface of epiglottis is supplied 
by the glossopharyngeal nerve and the laryngeal surface of the epiglottis is supplied by 
the vagus nerve. Internal laryngeal branch of superior laryngeal branch provides sensory 
supply to the supraglottic area. The recurrent laryngeal nerve ascends to the larynx in the 
groove  between  the  esophagus  and  trachea  and  divides  into  motor  and  sensory 
branches.14
The  motor  branch  supplies  all  the  intrinsic  muscles  of  the  larynx  except 
cricothyroid.
The sensory branch supplies the laryngeal mucous membrane below the level of 
vocal cords.
PHYSIOLOGY
        OF 
 STRESS RESPONSE
NERVE SUPPLY OF LARYNX
THE VAGUS NERVE AND ITS BRANCHES & 
THE GLOSSOPHARNYGEAL NERVE AND ITS BRANCHES
PHYSIOLOGY OF STRESS RESPONSE17
Haemodynamic stress response to laryngoscopy and intubation occurs as increase 
in the heart rate and the mean arterial pressure due to reflex sympathetic discharge in 
response to laryngo - tracheal stimulation.
 Tracheal  intubation alters respiratory and cardiovascular  physiology by reflex 
response  and  also  by  the  physical  presence  of  endotracheal  tube.  Although  these 
circulatory responses are transient and of little consequence in patients with normal 
circulatory system, they may be exaggerated in patients with coronary artery disease, 
reactive airways and intracranial pathology.
CARDIOVASCULAR RESPONSE
 This  transitory  variable  and  unpredictable  response  is  mediated  by  both 
sympathetic  and  parasympathetic  nervous  systems.  Usually  bradycardia  seen  in 
neonates and infants during laryngoscopy and intubation is the autonomic equivalent of 
Laryngospasm response in adults. This reflex is mediated by an increase in vagal tone 
at the SA node and is virtually a monosynaptic response to a noxious stimuli in the 
airway.14, 21
The  more  common  response  to  tracheal  intubation  is  hypertension  and 
tachycardia  mediated  by  sympathetic  efferents  via  the  cardioaccelarator  nerves  and 
sympathetic chain ganglia .The polysynaptic nature of pathways from the IX and X 
nerve afferents to the sympathetic nervous system via the brain stem and spinal cord 
results  in  a  diffuse  autonomic  response  which  includes  widespread  release  of 
norepinephrine  from the  adrenergic  terminals  and  release  of  epinephrine  from the 
adrenal medulla. 
One  other  reason  for  the  hypertensive  response  is  due  to  activation  of  renin-
angiotensin system with release of renin from the renal juxtaglomerular apparatus, an 
end organ innervated by adrenergic nerve terminals.
RESPIRATORY PHYSIOLOGY
 Glottic closure reflex [laryngospasm]
 Reduction in dead space.
 Increase in Airway resistance.
 Bronchospasm as a reflex response to intubation.
 Removes the glottic barrier and may lower lung volume.
 Cough efficiency is reduced.
 LARYNGOSCOPY 
&
ENDOTRACHEAL 
INTUBATION
POSITION FOR ENDOTRACHEAL INTUBATION
LARYNGOSCOPY AND ENDOTRACHEAL 
INTUBATION17,20
Direct laryngoscopy is visualization of the larynx under direct vision by the use of 
a mechanical device namely laryngoscope.
Endotracheal intubation is the trans laryngeal placement of a tube into the trachea 
via the nose or mouth.
TECHNIQUE FOR ORO TRACHEAL INTUBATION:
This  is  a  technique  which  requires  training  and  experience  to  make  it  safe, 
effective and least traumatic.
Equipments needed are laryngoscope, proper size endotracheal tube, appropriate 
anaesthetic drugs. suction apparatus, multimonitor, and facilities for IPPV of the lungs 
with oxygen.
Patient is positioned in Modified Jackson or sniffing position, and head is elevated 
by 10 centimeters with pads under the occiput , the cervical spine is maintained straight 
and the extension is made at the atlanto occipital joint. So as to make the patient’s head 
in level with the anesthetist’s xiphiod cartilage 20
Procedure:
The laryngoscope is held in the left hand near the junction of the handle and the 
blade, and is inserted on the right side of the patient’s mouth to deflect the tongue away 
from the line of vision; the laryngoscope handle must be maintained perpendicular to the 
plane of the patient’s body. After placing the blade in the mouth gentleness and avoiding 
of pressure on the upper teeth or gums are essential.
The handle should never be levered towards the anesthetist and the pull should be 
in the long axis of the handle. The epiglottis is visualized and the tip of the curved blade 
is slid into the vallecula between the base of tongue and the epiglottis. The subsequent 
forward  and  upward  movement  of  the  blade  exerted  along  the  axis  of  the  handle 
stretches the hyoepiglottic ligament causing the epiglottis to move upward and expose 
the glottic opening 20.
Placement of Endotracheal tube:
The glottic opening is recognized by its triangular shape and the pale white vocal 
cords. The ETT is held in the hand like a pencil and introduced on the right side of the 
patient’s mouth with the built in curve directed anteriorly. The tube is advanced till the 
cuff just disappears behind the cords. The laryngoscope is then with drawn and the cuff 
is inflated after verifying the air entry on both sides. 
PHARMACOLOGY 
OF 
LIGNOCAINE
PHARMACOLOGY OF LIGNOCAINE8
Lignocaine was synthesized by Lofgren in Sweden in 1943.
Lofgren  and  Lundquist  discovered  the  anaesthetic  properties  of  lignocaine  in 
1948, which was then introduced into clinical practice in 1949 by Gordon.20
STRUCTURE: 
 
CHEMICAL NAME: 
N-diethyl  aminoacetyl  2,6xylidine  hydrochloride  monohydrate.  It  contains  a 
tertiary amine attached to an aromatic system by an intermediate chain. Tertiary amine is 
a base. Lignocaine is 65% protonated at PH 7.4.
SODIUM CHANNEL
Molecular weight of the base is 234 and that of hydrochloride salt is 270. Its Pka 
is 7.9.
MECHANISM OF ACTION:
The action of the local anaesthetic is on the cell membrane of the axon, on which 
it produces electrical stabilization. The transient increase in the permeability of sodium 
ions necessary for propagation of the impulse is prevented, thus the resting membrane 
potential is maintained and depolarization in response to stimulation is inhibited.
They act by blocking the voltage gated sodium and potassium channels on the 
internal  nerve  cell  membrane.  The  sodium channel  protein  is  bell  shaped with  four 
transmembrane domains arrayed symmetrically around a central pore that splits into four 
passages that communicate between the intra and extracellular spaces.
The four  homologous domains [I-IV] contain six  transmembrane alpha-helices 
[S1-S6] and an inactivating particle connecting domains III  and IV.  The S5 and S6 
segments and the short loops between them form the pore. The fourth helix [S4] has 
positively charged arginine or lysine residues at every third position and is regarded as 
the voltage sensitive region of the sodium channel. The local anaesthetic binding site is 
located in the pore lining transmembrane segment 6 of domain I,III and IV8.
Three major conformational states of the sodium channel exist they are resting, 
open and inactivated.
 In contrast to voltage gated sodium channels, potassium channels are a diverse 
family of membrane proteins with many subtypes, although their distribution in nerve 
cells is not clear, they fulfill a number of roles in peripheral nerves, such as establishing 
the resting membrane potential and accomplishing repolarisation8.
Local anaesthetics bind to the sodium receptors on domain IV, loop S6 and cause 
blockade of these channels. The affinity is higher in the open or inactivated states than in 
the resting state. As a result the height of action potential is reduced, the firing threshold 
is  elevated,  the  spread  of  impulse  conduction  is  slowed  and  the  refractory  period 
lengthened. Finally nerve conduction is completely blocked.
Recent evidence has highlightened the many diverse actions of local anaesthetics. 
They  also  interact  with  G-protein  coupled  receptors,  muscarinic  receptors  and 
endothelial nitric oxide.
Attachment  of  local  anaesthetics  to  G-protein  coupled  receptors  linked  to 
lysophosphatalic acid attenuates neutrophil, macrophage and monocyte function.
Lignocaine  has  reduced  the  surface  expression  of  adhesion  molecules  on 
polymorphonucleocytes,  reduced  priming  of  PMN  by  cytokines,  and  reduced 
chemotaxis, lysozyme release and free radical production.8, 17
PHARMACODYNAMICS:
 CARDIOVASCULAR SYSTEM:
It stabilizes the electrical activity of any excitable tissue. It stabilizes the aberrant 
conduction and the automaticity in abnormal or damaged fiber and suppresses cardiac 
arrthymias. It is useful in the treatment of ventricular arrhythmias that occur following 
myocardial infarction or cardiac surgery.20
 
It  causes  vasoconstriction  at  low  concentration  and  vasodilatation  at  higher 
concentration due to stimulation and inhibition of calcium release.
 CENTRAL NERVOUS SYSTEM:
It produces sedation, light headedness while sometimes anxiety and restlessness 
occur. With more marked toxicity circum oral numbness, muscle twitchings and visual 
disturbances can occur. Severe toxicity proceeds to convulsions and coma as a result of 
medullary depression.
PHARMACOKINECTICS17, 20:
Absorption is slow in regional anaesthesia where as when given intravenously, 
peak levels are reached immediately. It is metabolized in the liver-amide hydrolysis by 
microsomal  enzymes,  ring  hydroxylation  and  dealkylation.  Its  metabolite 
monoethylglycine xylidide is moderately toxic and effective antiarrhythmic. Its volume 
of distribution is 91l and the clearance is 95 l/min.
Dosage and Administration:
 Cardiac arrhythmias:1-2 mg/kg IV bolus followed by an infusion at the rate of 
4mg/min and reduced to 2mg/min over a period of 2-4 hours.
 To attenuate the cardiovascular response to intubation 1.5mg/kg 3 minutes prior 
to laryngoscopy.
 For treatment of status epilepticus:  Initial  injection of 2mg/kg followed by IV 
infusion at the rate of 6 mg/kg/hr for a maximum of 5 hours.8
CONTRAINDICATIONS
 Known hypersensitivity to local anaesthetics of amide group such as prilocaine, 
mepivacaine or bupivacaine.
 Adams-stroke syndrome, or severe degree of sinoatrial, or atrioventricular block.
SAFE DOSE:8
Without adrenaline: 3mg/kg.
With adrenaline     : 7mg/kg.
AVAILABLE PREPARATIONS:
1) 5%(heavy)for spinal Anaesthesia.
2) 1% and 2% vial for Nerve blocks and Epidural Anaesthesia(with and without 
adrenaline)
3) Lignocaine hydrochloride 2%(without preservative) for intravenous use.
4) 4% Topical  spray.
5) 2.5% Lignocaine in combination with 2.5% Prilocaine as EMLA.
6) 2.5 – 5 % ointment.
7) 2%  Jelly.
8) 2% Viscous.
9) 10% suppositories.
10) 10% Aerosol.
11 )5% Topical patch.
12)15%spray.
13)2%Lignacaine with adrenaline.
PHARMACOLOGY
OF
MAGNESIUM 
SULPHATE
PHARMACOLOGY OF MAGNESIUM SULPHATE
It is a bivalent ion like calcium with an atomic weight of 24.312.
Human body contains 1 mole (24g) of magnesium. It is the fourth common mineral salt 
in the body after phosphorus, calcium and potassium, second intracellular cation after 
potassium. In serum magnesium is divided into three fractions-
 Ionised,
 Protein bound and
 Contained in anion complexes. 
These fractions account for 65%, 27%, and 8% in serum concentrations. respectively. 2, 
12
STRUCTURE OF MAGNISIUM SULPHATE12:
Magnesium sulphate
PROPERTIES OF MAGNESIUM SULPHATE:2
 CELLULAR PROPERTIES:
Magnesium intervenes in the activation of membrane calcium ATPase and Na  - K 
ATPase  involved  in  transmembrane  ion  exchange  during  depolarization  and 
repolarization  phases.It  acts  as  a  stabilizer  of  cell  membrane  and  intracytoplasmic 
organelles.
 ION CHANNELS:
It  acts  as  a  regulator  of  different  ion channels.It  has  a  competitive antagonist 
action  against  calcium  inflows  there  by  limits  the  outflow  of  calcium  from  the 
sarcoplasmic  reticulum.So  it  is  a  calcium  channel  blocker   and  calcium  channel 
modulator. It is involved in hundreds of enzyme reactions in the body.
 CARDIOVASCULAR SYSTEM:
It acts on calcium channels in the myocardial muscle and also acts directly on the 
cardiac muscle by inhibiting the calcium uptake on the troponin C of the myocytes and 
thereby influencing myocardial contractility.
Its vasodilatory action is due to its activation of cyclic AMP. This causes 
reduction in systolic blood pressure.
Coronary vascular resistance is reduced and causes vasodilatation but pulmonary 
vascular resistance is unaltered.
 NEURO MUSCULAR TRANSMISSION:
It has a preponderant presynaptic and postsynaptic effect.
Magnesium acts competitively in blocking the entry of calcium into the presynaptic 
endings.  Presynaptic  release  of  acetylcholine  is  reduced  by  magnesium,  thereby 
decreasing  the  effect  of  acetylcholine  on  the  postsynaptic  receptors,  which  in  turn 
increases the threshold of axonal excitation.
It also produces progressive inhibition of catecholamine release from the adrenal 
medulla, adrenergic nerve endings and adrenergic post ganglionic sympathetic fibers.
 Acts as a antagonist  of  NMDA receptors,  and this explains its  use in post-op 
analgesia. 
 Magnesium  sulphate  increases  production  of  prostaglandins  causing 
vasodilatation  of  the  small  intracranial  vessels  which  is  responsible  for  its 
anticonvulsant action.
 RESPIRATORY SYSTEM:
It has bronchodilatory action due to the inhibition of smooth muscle contraction, 
histamine release from the mast cells and acetylcholine release from the cholinergic 
nerve endings.
PHARMACOKINETICS: 2, 17
Absorption:
Following  intravenous  administration,  onset  of  action  is  immediate  and 
following intramuscular administration it takes about 1 hour for the onset of action.
Duration:
The duration of action following intravenous administration is about 30 minutes 
and following intramuscular route of administration the duration of action is about 3 to 
4 hours.
Distribution:
Magnesium can cross placenta and also secreted in milk.
Elimination:
Metabolized in the liver and excreated through the kidneys; there is 
interindividual variability but the rate of excretion is directly propotional to the serum 
conecentration and glomerular filtration .
CLINICAL USES:
• For Severe Pre-eclampsia and Eclampsia: A loading dose of 4-6gm Magnesium 
sulphate diluted in 100ml of Normal Saline given over 15min intravenously. Then 
2 gm/hr in 100ml of intravenous infusion (maintain serum levels between 4 and 
7mEq/L).
Intermittent injection:
 4gm magnesium sulphate  is   given slowly  by intravenous  route  followed by 
10gm,5gm in each buttock as  deep  intramuscular  injection.  Then every  4hrs  5gm 
intramuscularly upto24hrs after delivery.
• Magnesium sulphate has a tocolytic effect at serum levels of 8-10mEq/L. Loading 
dose  of  4-6gm  over  20min  intravenously,  then  after  the  contraction  ceases 
maintenance is done using 2-4gm per hour intravenously for 12-24 hours.
• To reduce the stress response during intubation-Magnesium sulphate is used in the 
dosage of 30-50mg/kg. intravenously.
• In surgery for phaeochromocytoma it helps to maintain haemodynamic balance 
because it inhibits the catecholamine release from adrenal medulla and adrenergic 
nerve endings.
• Nephritic  Seizures:  In  children  with  nephritic  seizures,  the  50% concentration 
should be diluted to a 20% solution for intramuscular.  injection. The dose for 
children is 20 to 40 mg (0.1 to 0.2 mL of a 20% solution)/kg of body weight, 
administered intramuscularly as needed, to control seizures.
• It is used postoperatively in patients who have undergone coronary artery bypass 
grafting to reduce the incidence of ventricular arrhythmias.
• It is also used in the treatment of Torsades De Pointes, as intravenously or intra 
osseously in the dosage of 25 to 50 mg/ kg (upto 2 gm).
• Acute Myocardial Infarction:  Magnesium sulphate is used in the dose of 2gm 
intravenously over 5-15 min followed by 18 gm over 24hrs as infusion.
• Total Parenteral Nutrition: In total parenteral nutrition, maintenance requirements 
for magnesium are not precisely known. The maintenance dose recommended for 
adults is 5 to 8 mEq magnesium/L of total parenteral nutrition solution; typical 
daily adult intake ranges from 10 to 24 mEq. For infants, the recommended intake 
ranges from 0.25 to 0.6 mEq/kg/day.
• In barium poisoning: 1-2gm is used to counteract the intense muscle stimulating 
effects of barium.
• In refractory bronchial asthma it is used for its bronchodilatory action.
• Hypomagnesemia: in case of mild deficiency 1gm every 6 hours for 4 doses, in 
severe cases 1-5gms (2 – 10ml of 50% solution) in divided doses, repeated until 
the serum levels are normal.
• Recent  studies  show its  use  in  Tetanus  patients,  at  a  serum concentration  of 
2-4mEq/L, it gives good control of spasms and muscle rigidity.
PRECAUTIONS:
Because magnesium is removed from the body solely by the kidneys, the drug 
should be used with caution in patients with renal impairment. Urine output should be 
maintained at a level of 100 ml every 4 hours.
 Monitoring serum magnesium levels and the patient's clinical status is essential to 
avoid the consequences of over dosage in toxemia.
Clinical indications of a safe dosage regimen include the presence of the patellar 
reflex (knee jerk) and absence of respiratory depression (approximately 16 breaths or 
more/minute). Serum magnesium levels usually sufficient to control convulsions range 
from 3 to 6 mg/100 ml (2.5 to 5.0 mEq/L). The strength of the deep tendon reflexes 
begins to diminish when magnesium levels exceed 4 mEq/L.
Reflexes may be absent at 10 mEq magnesium/L, where respiratory paralysis is a 
potential  hazard.  An  injectable  calcium  salt  should  be  immediately  available  to 
counteract the potential hazards of magnesium intoxication in eclampsia. 
Parenteral drug products should be inspected visually for particulate matter and 
discoloration prior to administration, whenever solution and container permit. Do not 
administer unless solution is clear and container is undamaged. Discard unused portion.
PREPARATIONS AVAILABLE:2, 8
Parentral injection:Magnesium sulphate-10%, 12.5%, 50%
For Intravenous use only-4%, 8%.
Magnesium sulphate in dextrose: 1% in 5%dextrose.
                      2%in 5% dextrose.
When administered intravenously the onset of action is immediate and duration of 
action is 30 min. on administration by intramuscular route the onset of action takes 1hr 
and duration of action is 3-4 hrs.
Storage:  15-30degree centigrade.  For intravenous use concentration of 20% or 
less should be used. Rate of injection should be 1.5ml/hr.
DRUG INTERACTIONS:
Central Nervous System Depressants: When barbiturates, opiates, general anesthetics, 
or  other  CNS depressants  are  administered  concomitantly  with  magnesium sulfate, 
dosage  of  these  agents  must  be  carefully  adjusted  because  of  the  additive  central 
depressant effects. 
Neuromuscular Blocking Agents: Excessive neuromuscular blockade has occurred in 
patients receiving parenteral magnesium sulfate and a neuromuscular blocking agent; 
these drugs should be administered concomitantly only with caution. 
Cardiac Glycosides: Magnesium salts should be administered with extreme caution in 
digitalized patients, because serious changes in cardiac conduction, which can result in 
heart  block,  may occur if  administration of  calcium is required to treat  magnesium 
toxicity.8 
ADVERSE REACTIONS:
The adverse effects of parenterally administered magnesium usually are the result 
of magnesium intoxication. These include flushing, sweating, hypotension, depressed 
reflexes,  flaccid  paralysis,  hypothermia,  circulatory  collapse,  cardiac  and  CNS 
depression  proceeding to  respiratory  paralysis.  hypocalcaemia,  with  signs  of  tetany 
secondary to magnesium sulfate therapy for eclampsia, has been reported. 
SYMPTOMS AND TREATMENT OF OVERDOSE: 
Magnesium intoxication  is  manifested  by  a  sharp  drop  in  blood pressure  and 
respiratory paralysis. Disappearance of the patellar reflex is a useful clinical sign to 
detect the onset of magnesium intoxication.
 In the event of over dosage, artificial ventilation must be provided until a calcium 
salt can be injected intravenously to antagonize the effects of magnesium. 
In adults, intravenous administration of 5 to 10 mEq of 10% calcium gluconate 
will  usually  reverse  respiratory  depression  or  heart  block  due  to  magnesium 
intoxication. 
In extreme cases, peritoneal dialysis or hemodialysis may be required.
Hypermagnesemia  in  the  newborn  may  require  resuscitation  and  assisted 
ventilation via endotracheal intubation or intermittent positive pressure ventilation, as 
well as intravenous calcium. 17
MATERIALS 
&
METHODS
MATERIALS AND METHODS
After approval of the study by our institutional Ethics Committee, a total of 40 
patients of both sexes in the age group between 15-50years, belonging to ASA grade I 
undergoing  elective  surgery  under  general  anaesthesia  were  included  in  this  double 
blinded, randomized, clinical study.
Informed  written  consent  was  obtained  from  all  the  patients.  Patients  were 
assessed  by  detailed  history  and  physical  examination,  supported  by  routine 
investigations (Haemoglobin percentage, Blood glucose, urea, creatinine, ECG, X - ray 
chest PA view.)
INCLUSION  CRITERIA are patients belonging to ASA grade – I, MPG grade – I, and 
laryngoscopy time less than 15 seconds.
EXCLUSION  CRITERIA for the study includes patients belonging to ASA grade more 
than one., MPG > 1, predicted  difficult airway, systemic hypertension, coronary artery 
heart  disease,  diabetes mellitus,  patients on antihypertensives and cardiac drugs,  and 
valvular heart diseases.
Out of the 40 patients 20 were randomly included in the L group (LIGNOCAINE 
GROUP) and  the  other  20  were  included  in  the  M  group  (MAGNESIUM  SULPHATE 
GROUP).
All  the  patients  were  premedicated  with  injection  Glycopyrolate  0.01mg/kg 
intramuscularly 45minutes prior to surgery.
Patients were shifted to the operation theatre and connected to the noninvasive 
multimonitor, and intravenous access was obtained using 18G cannula.
Baseline Heart rate, Blood pressure (Mean arterial pressure), SPO2 were recorded.
The  patients  were  preoxygenated  with  100%  oxygen  for  3  minutes.  All  the 
patients received injection fentanyl 1mcg/kg intravenously. 
Two minutes after the administration of fentanyl,  patients in L group received 
injection  Lignocaine  1.5mg/kg  and  the  patients  in  the  M  group  received  injection 
Magnesium sulphate 30mg/kg intravenously.
 
One  minute  after  that  the  patients  were  induced  with  injection 
Thiopentone5mg/kg and injection atracurium 0.5mg/kg intravenously. Then the patients 
were mask ventilated with 100% oxygen and after 3 minutes heart rate, blood pressure 
(mean arterial pressure) were noted and taken as the post induction value.
Laryngoscopy and Intubation was done using appropriate size Macintosh blade 
and appropriate size endotracheal tube.
Measurement of heart rate, blood pressure (Mean arterial pressure) and SPO2 was 
done immediately after laryngoscopy and at one, three and five minutes after placement 
of the endotracheal tube. Surgical incision was allowed after the last measurement.
Syringes were prepared by a postgraduate who did not take part in the study and 
the  injections  were  given  by  him.  Intubation  was  performed  by  an  experienced 
anaesthesiologist who was double blinded to the drugs given.
Neuromuscular blockade was monitored using the nerve stimulator with train of 
four for every 5 minutes after intubation upto 45minutes.
The incidence of complications like hypotension, arrhythmias, nausea, flushing, 
sweating were recorded until the patient was discharged from the post anaesthesia care 
unit.
RESULTS
RESULTS
The present study was undertaken in 40 ASA grade I patients of both gender 
between the age group of 15-50 years scheduled for elective surgeries under general 
anaesthesia. The patients were categorized into 2 groups [Lignocaine group and 
Magnesium group].
Statistical Analysis
We used students independent “t” test to compare various factors between the two 
groups. Results were expressed as mean and standard deviation (Mean + SD) Chi-square 
test was done to compare proportions, and values less than 0.05 was considered as 
statistically significant.
 (Table: 1) (Figure: 1)
Table: 1 DEMOGRAPHIC CHARACTERISTICS BETWEEN GROUPS
PARAMETERS
GROUP –L 
(n=20)
GROUP – M 
(n=20)
P value
Mean Age in Yrs 
(+S.D.)
34.3 + 8.86 34.2 + 8.22 0.97
Mean weight in 
Kgs (+S.D.)
53.5 + 3.38 52.8 + 4.40 0.54
(S.D. – Standard deviation)               (P > 0.05)
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Figure: 1
The groups were matched for demographic data, and there was no statistically 
significant difference found between the groups in age, sex, weight and surgical 
position.
With patient on table before giving Lignocaine or Magnesium sulphate, baseline 
heart rate and mean arterial pressure were recorded for the two groups (Table: 2) and 
(Table: 3) respectively. There was no significant difference in heart rate and MAP 
between the 2 groups.
Table: 2 BASELINE HEART RATE.
BASELINE HR GROUP – L GROUP – M
MEAN + S.D. 86.8 + 5.063 87.25 + 4.529
(HR – Heart rate)                     ( P > 0.05)              Figure :2
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Table : 3 BASE LINE MEAN ARTERIAL PRESSURE.
BASELINE MAP GROUP – L GROUP – M
MEAN + S.D. 93.6 + 10.1 95.9 + 9.49
(MAP – Mean Arterial Pressure)                 (P > 0.05)         Fig.3
After the drug was administered intravenously any deviation from the baseline 
values were recorded following induction, laryngoscopy, and intubation. (1 minute, 3 
minutes, and 5minutes) (Table: 4, Table: 5)
       Figure: 3
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93.8
94.6
GROUP L
GROUP M
Table: 4 DEVIATION OF HEART RATE FROM BASELINE.
HEART RATE
GROUP – L
MEAN + S.D
GROUP – M 
MEAN + S.D.
P VALUES
POST 
INDUCTION 80.85 + 5.31 75.8 + 3.95 0.002
POST 
LARYNGSCOPY 84.4 + 4.75 78 + 4.18 0.0001
POST 
INTUBATION 
(1 min.)
86.2 + 4.77 79.3 + 4.02 0.0001
POST 
INTUBATION 
(3 min.)
84.4 + 4.82 77.4 + 4.19 0.0001
POST 
INTUBATION 
(5 min.)
83 + 4.36 75.8 + 4.14 0.0001
(P < 0.005)
There was fall in heart rate (P < 0.05) noted following induction, laryngoscopy, 
and intubation, in Magnesium group and Lignocaine group, but the fall in heart rate was 
more  significant  in  the  Magnesium  group  when  compared  with  the  Lignocaine 
group.Fig.4,5
Figure: 4
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Table : 5 DEVIATION OF MEAN ARTERIAL PRESSURE FROM 
BASELINE.
COMPARISON OF HEART RATE
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GROUP L
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MAP
GROUP – L
MEAN + S.D
GROUP – M
MEAN + S.D.
P VALUES
POST 
INDUCTION
87.7 + 9.35 81.8 + 17 0.021
POST 
LARYNGSCOPY
91.3 + 9.23 85.6 + 7.17 0.035
POST 
INTUBATION 
(1 min)
92.7 + 10 86.7 + 6.78 0.032
POST 
INTUBATION 
(3 min)
91.2 + 9.84 85 + 6.92 0.028
POST 
INTUBATION 
(5 min.)
90.2 + 9.96 83.5 + 6.65 0.017
 (MAP – Mean arterial pressure)             (P < 0.05)
Like heart rate there was a significant fall in mean arterial pressure in both the 
groups, but there was statistically significant fall (P < 0.05) in the Magnesium group 
when compared with the Lignocaine group. Fig 6,7
Figure: 6
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Table : 6 AVERAGE VALUES OF TRAIN OF FOUR.
COMPARISION OF MEAN ARTERIAL PRESSURE
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TOF IN MINUTES GROUP – L GROUP – M P VALUE
MEAN + S.D. 25.5 + 4.84 26.5 + 4.89 0.52
(P > 0.05)
The train of four values was recorded every 5 minutes upto 45 minutes following 
drug  administration  and  the  duration  needed  for  the  return  of  third  twitch  using 
neuromuscular  monitoring  was  recorded.  This  showed  no  statistically  significant 
difference between the 2 groups.        (P >0.05). (Table: 6)
The incidence of complications for magnesium like hypotension, sweating, 
arrhythmia, nausea, flushing, and hot sense were watched for until the patients were 
discharged from post anaesthesia care unit. There were no such complications observed 
in this study.
REVIEW
OF
LITERATURE
REVIEW OF LITERATURE
The  haemodynamic  consequences  of  endotracheal  intubation  have  been  the 
subject of study by various authors over many years
Tachycardia and hypertension commonly occur during anaesthesia due to many 
factors  like  mechanical  stimulation,  abnormal  level  of  electrolytes  and  complex 
interaction of hypoxia, hypercapnia and circulating levels of catecholamines.17
Gray  &  Nunn22n  their  study  proved  “Laryngoscope  and  intubation  are  the 
commonest  cause  of  transient  hypertension  and  arrhythmias  during  anaesthesia. 
Fortunately the arrhythmias normally disappear once the tube is in place.”
King et.al16. in 1951.showed that there was a marked rise in blood pressure and 
heart rate during laryngoscopy which was due to the mechanical stimulation of sensitive 
receptors in the area of epiglottis.
Baumgartner & Mycoft concluded in their study that “Succinyl choline produces 
transient rise in blood pressure accompanied by bradycardia”
Collins et.al. 17 proved that “ Deep pressure on the base of the tongue and on the 
neck muscle is responsible for the rise in blood pressure and heart rate .
Chung et.al. 20in their  study on haemodynamic responses to laryngoscopy and 
intubation showed maximum value of systolic , diastolic , mean arterial pressure and 
heart rate occur within 30 to 60 seconds of laryngoscopy and intubation, and in patients 
with  hypertension,  laryngoscopy and intubation led to  left  ventricular  failure  due  to 
exaggerated  pressure  response.  Similarly  in  patients  with  IHD  transient  myocardial 
ischaemia has been observed.
Aries & simonies 18have correlated the levels of adrenaline and nor adrenaline 
with sympathetic innervation.”
Roberts, C. Green, et. al  22showed an exaggerated form of rise in heart rate and 
mean arterial pressure in hypertensive patients during laryngoscopy and intubation.
A.J. Shribiran, G. Smith et. al.19 in a study of haemodynamic stress response to 
laryngoscopy alone and laryngoscopy followed by intubation, was done in 24 patients 
and the heart rate, MAP, and the plasma catecholamines before laryngoscopy and at 1st, 
3rd, and 5th min after laryngoscopy was assessed. There was a significant increase in the 
heart  rate,  mean arterial  pressure  and plasma catecholamine  concentration following 
laryngoscopy with or without intubation.19
R.W.Allen,M.B,CH.B,F.F.A.R.C.S.I,and M.F.Mjames,P.C.Uys6 in  their  study  on 
attenuation of  the pressor  response to  tracheal  intubation in  hypertensive proteinuric 
pregnant  patients  they compared lignocaine and magnesium sulphate  40mg/kg in  69 
patient and found that the attenuation of heart rate and MAP was more significant in the 
Magnesium group.6
Similarly  D.H.Van  ziji,P.C.Gordon  and  M.F.James20ompared  the  effects  of 
Remefentanil  or Magnesium sulphate with placebo in attenuating the haemodynamic 
response  after  electroconvulsive  therapy  and  found  significant   response  with 
magnesium sulphate.3
Michael F. M. James, FFARCS, R. Eryk Beer, FFA(SA), and Jan D. Esser3,  
MMED  in  their  study  on “Intravenous  Magnesium Sulfate  Inhibits  Catecholamine 
Release  Associated  with  Tracheal  Intubation” showed  pretreatment  with  Magnesium 
sulphate 60mg/kg in 15 patients compared with normal saline found that Magnesium 
group patients  had decrease in heart  rate and mean arterial  pressure and the plasma 
levels of epinephrine was unchanged after intubation.3
Puri GD et. al 4showed the effect of magnesium sulphate on haemodynamics and 
its  efficacy  in  attenuating  the  response  to  endo  tracheal  intubation  in  patients  with 
coronary  artery  disease,  concluded  magnesium  administration  at  the  time  of  the 
induction  of  anesthesia  improves  hemodynamics  in  patients  with  CAD  undergoing 
CABG and is associated with lesser hemodynamic and ST segment changes compared 
with  lidocaine  at  the  time  of  endotracheal  intubation  in  these  patients.  When 
administering  magnesium  sulfate,  however,  one  should  be  aware  of  the  adverse 
hemodynamic interactions inpatients with CAD receiving calcium channel blockers, B-
adrenergic blockers and ACE inhibitors for antihypertensive therapy.
 N.  M.  Elsharnouby, and M. M.  Elsharnouby13  in  their  paper  on  Magnesium 
sulphate as a technique of hypotensive anaesthesia  studied sixty patients (25 female) 
undergoing functional endoscopic sinus surgery in two parallel groups. The magnesium 
group received  Magnesium sulphate  40  mg  kg–1 i.v.  as  a bolus  before  induction  of 
anaesthesia and 15 mg kg–1 h–1  by continuous i.v. infusion during the operation. The 
same volume of isotonic solution was administered to the control group. Intraoperative 
bleeding was  evaluated  using  a  quality  scale,  showed  Magnesium sulphate  led  to  a 
reduction in arterial pressure, heart rate, blood loss and duration of surgery. Furthermore, 
magnesium infusion alters anaesthetic dose requirements and emergence time
G M Sanders, FRCA, K M Sim, M Med (Anaes)15 in their study
Is it Feasible to Use Magnesium Sulphate as a Hypotensive Agent in
Oral and Maxillofacial Surgery?
They have demonstrated that the use of intravenous Magnesium sulphate infusion 
for  intraoperative  deliberate  hypotension  is  feasible  in  ASA  1  patients  undergoing 
standard  nitrous  oxide,  oxygen,  isoflurane,  opioid  and  muscle  relaxant  anaesthesia. 
Blood  loss  appears  to  be  less  than  with  other  hypotensive  anaesthetic  techniques. 
Intraoperative  control  of  blood  pressure  was  satisfactory without  undesirable 
cardiovascular  side  effects  and  postoperative  muscle  weakness  was  not  a  problem 
clinically.
In a Dose – Response Study of Magnesium Sulfate in Suppressing
Cardiovascular Responses to Laryngoscopy and Endotracheal Intubation.
By K. Montazeri MD, M. Fallah MD.1on 120 ASA – 1 patients classified into 6 
groups  of  20  each  Magnesium sulphate  was  given  in  the  doses  of  10,  20,  30,  40, 
50mg/kg each and compared with lignocaine 1.5mg / kg. The induction of anesthesia 
was same in all groups and the pulse rate and arterial blood pressure were measured and 
recorded just before intubation and also at 1, 3, and 5 minutes after intubation before 
surgical incision.
In  their  conclusion  they  proved  that  administration  of  different  doses  of 
Magnesium sulphate intravenously at the time of the induction of anesthesia improves 
hemodynamic  responses  to  endotracheal  intubation.  They  found  that  the  dose  of 
30mg/Kg of Magnesium sulphate was most effective with least adverse effects.
On intravenous Magnesium sulfate as a preanesthetic medication:
Tetsuro Kagawa et. al.11 in their double-blind study on its effects on hemodynamic 
stabilization at the time of tracheal intubation showed the effects of Magnesium sulfate 
(MgSO4) as a preanesthetic medication with regard to whether it can sedate or relieve a 
patient  who  is  scheduled  to  undergo  surgery,  and  whether  it  can  control  the 
hemodynamic response to tracheal intubation. Twenty adult patients in ASA status I–II 
undergoing elective surgery were studied. Magnesium sulphate was given in dose of 50 
mg/kg intravenously by drip infusion from 30 min before the induction of anesthesia and 
saline was used as a control.  The changes in mean arterial  pressure (MAP) and rate 
pressure product (RPP) after the intubation were significantly suppressed in magnesium-
treated patients, but a sedative effect was not observed in their study. Therefore, they 
concluded Magnesium sulphate was useful as a preanesthetic medication in suppressing 
the hemodynamic response associated with tracheal intubation.
Naghibi KH, Akhtari M et. al.7 in their study of attenuation of pressor responses to 
trachaeal  intubation  by  Magnesium  sulphate,  showed  a  reduction  in   mean  arterial 
pressure and tachycardic response in patients  who were pre treated with magnesium 
sulphate intravenously, with very low sedative effect.
DISCUSSION
DISCUSSION
Calcium  exerts  a  major  role  in  stimulus-response  relationship,  including  the 
release  of  catecholamines  from the  adrenal  gland and adrenergic  nerve  terminals  in 
response to sympathetic stimulation. Because Magnesium competes with calcium for 
membrane channels, it has been described as the physiological calcium antagonist and 
can modify many calcium mediated responses.10
The ability of magnesium ions to inhibit the release of catecholamines from both 
the adrenal glands and peripheral adrenergic nerves terminals has been known for many 
years. It also produces vasodilatation, directly.
G.D.  Puri  et.al.  4n  their  study  on  the  effect  of  Magnesium  sulphate  on 
haemodynamics and its efficiency in attenuating the response to endotracheal intubation 
in  patients  with  coronary  artery  disease,  studied  36  patients,  of  which  one  group 
received 50mg/kg of  Magnesium sulphate  intravenously  and another  group received 
1mg/kg Lignocaine intravenously. 
Their results showed a decrease in mean arterial pressure from basal values of 91+ 
14.5 to 86 .6+ 14.5 mm of Hg after intubation (P<0.05). The heart rate showed a mild 
increase from 65.2+ 12.7 to 69.7+ 13.7 beats/ minute (P < 0.001), and the cardiac index 
is  also  increased  (P<  0.01)  in  the  Magnesium sulphate  group  when  compared  with 
control group.
Three patients in the magnesium group and two patients in the control group had 
severe hypotension that needed pharmacological treatment. This fall was noted in the 
patients who were taking ACE inhibitors or beta-blockers for coronary artery disease 
and this potentiated the myocardial depressing effect of Magnesium sulphate. In this 
study  all  the  patients  were  ventilated  post  operatively,  so  the  enhancing  effect  of 
neuromuscular blockade was not studied.
On comparison with our study, in which we used Magnesium sulphate in the dose 
of  30mg/kg  intravenously  to  asses  the  cardiovascular  response  to  laryngoscopy  and 
intubation showed a decrease in heart rate  ( P < 0.005) and the mean arterial pressure 
also showed a decrease         (P < 0.05) on comparison with the Lignocaine group.
The increase in the heart rate noted in this study by G.D.Puri et.al.4 may be due 
the ability of Magnesium sulphate in higher doses to inhibit the release of acetylcholine 
from the vagal nerve predominantly. This theory was supported by Michael F.M. James, 
FFARCS,  R.  Eryk  Beer,  FFA(SA),  and  Jan  D.  Esser,  MMED24 in  their  study,  “ 
Intravenous Magnesium sulphate inhibits catecholamine release associated with tracheal 
intubation”  in  which  they  used  Magnesium  sulphate  in  the  dose  of  60mg/kg 
intravenously and their results showed an initial increase in heart rate by 13+ 3.9 beats/
minute.
This effect was not observed in our study as we used a dose of 30mg/kg, which 
was a lesser dose on comparison with their study.
The mean arterial pressure in both studies showed a declining trend, but three 
patients  in  the Magnesium sulphate  group in  their  study showed hypotension which 
required treatment, which was not observed in our study since we included ASA grade I 
patients,  who were not on any drugs acting on cardiovascular system preoperatively. 
However we should be aware of the adverse haemodynamic interactions of Magnesium 
sulphate in patients receiving cardiovascular drugs like ACE inhibitors, betablockers and 
calcium channel blockers.
In a dose response study of Magnesium sulphate in suppressing the cardiovascular 
responses to laryngoscopy and intubation done by K.Montazeri M.D., M.Fallah M.D.1 
studied  6 groups  of  patients  of  20 each with  varying doses  of  Magnesium sulphate 
(10,20,30,40,and 50mg/kg) and compared with the control using Lignocaine in the dose 
of  1.5mg/kg.  and  observed  that  there  was  significant  reduction   in  heart  rate  on 
comparison between Magnesium sulphate and Lignocaine groups      (P < 0.05). But 
within the magnesium groups the difference in heart rate was not significant (P > 0.05). 
Like  heart  rate  there  was  significant  fall  in  the  mean  arterial  pressure  when 
compared with the lignocaine group (P < 0.05), but the fall is not significant within the 
magnesium groups (P > 0.05) .
The train of four at 45 minutes after induction of anaesthesia in all groups had no 
statistically significant differences.
Adverse  effects  of  Magnesium sulphate  like  hypotension,  arrhythmia,  nausea, 
sweating and flushing, were observed in certain patients in higher doses.
Similarly  in  our  study  using  30mg/kg  of  Magnesium  sulphate  there  was  a 
reduction in the heart rate (P <0.05) and the mean arterial pressure (P<0.05), which was 
statistically significant when compared with the lignocaine group lending support to our 
study.  We  did  not  observe  any  side  effects  in  any  of  the  patients.  Similarly 
neuromuscular blockade was not significantly prolonged in our study as seen by the 
train of four values at 45 minutes.
In a study by G.M. Saunders FRCA, K.M. Sim M.Md (Anaes),15     “ Is it feasible 
to use Magnesium sulphate as hypotensive agent in oral and maxillo facial surgery?” 
studied 16 patients using Magnesium sulphate infusion at 40g/hr. until the mean arterial 
pressure reached to 55+ 5 mm Hg and followed by maintenance of 5g/hr until 30 min. 
prior to the end of surgery, their results showed decrease in mean arterial pressure and 
heart rate from a baseline during the surgery and which returned to baseline 26 minutes 
after the surgery. Train of four monitoring during surgery showed no response in all the 
patients  on  Magnesium  sulphate  infusion.  On  terminating  the  Magnesium  sulphate 
infusion the first tetanic contraction appeared with no fade, followed by train of four 
pattern similar to that seen with depolarizing neuromuscular blockers. There were no 
complications like reflex tachycardia or arrhythmias observed. 
This study corroborates with our study in the reduction of mean arterial pressure 
and heart rate significantly in intravenous use of Magnesium sulphate, but we altered the 
dose to 30mg/kg bolus, as they have used higher doses and observed few side effects 
like prolonged sedation postoperatively.
In  another  study  by  R.W.  Allen,M.B.,  CH.B.,  F.F.A.R.C.S.I,  M.F.M.  James, 
CH.B., P.C. Uys, CH.b. FFA (SA)6 in “ Attenuation of the pressor response to tracheal 
intubation in hypertensive proteinuric pregnant patients by Lignocaine, Alfentanil, and 
Magnesium  sulphate”.  they  used  Magnesium  sulphate  40mg/kg  intravenously  and 
observed an increase in the systolic, diastolic blood pressure and mean arterial pressure 
following intubation, in the lignocaine group when compared to the Magnesium group. 
Similarly the heart rate was decreased in the Magnesium sulphate group significantly 
when compared to the other two groups. Alfentanil caused least change in heart rate but 
caused  significant  fetal  depression.  Although  Magnesium  sulphate  and  Alfentanil 
provide adequate control of cardiovascular response in hypertensive patients, Alfentanil 
is less reliable in controlling severe hypertension.
This study corroborates with the evidences in our study that Magnesium sulphate 
intravenously  given  prior  to  induction  can  have  adequate  control  of  cardiovascular 
response to laryngoscopy and intubation.
Our present study lends support to previous studies that the use of Magnesium 
sulphate 30mg/kg intravenously one minute prior to induction reduces the heart rate and 
mean  arterial  pressure  in  response  to  laryngoscopy  and  intubation  in  a  favourable 
manner without any side effects.
SUMMARY
SUMMARY
This  study  was  conducted  in  40  ASA grade  I  patients  who were  admitted  at 
Thanjavur  Medical  College  Hospital  to  undergo  various  surgical  procedures  under 
general  anaesthesia  After  getting  Ethical  committee  approval  and  informed  written 
consent from the patients, the total of 40 patients were allocated into two groups of 20 
each. 
They were connected to the non-invasive monitors and the basal heart rate and 
mean arterial pressure were recorded. 
Magnesium sulphate  was  given  in  the  dose  of  30mg/kg  one  minute  prior  to 
induction for group M and Lignocaine 1.5mg/kg was given to group L.
The induction of anaesthesia was same in both groups and heart rate and mean 
arterial pressure were recorded following induction, laryngoscopy, and intubation at one, 
three, and five minutes (before the surgical incision). Train of four was recorded for 45 
min. from the time of induction for every 5 minutes until the third twitch appears in the 
neuromuscular  monitoring.  Patients  were  observed  for  side  effects  of  Magnesium 
sulphate like hypotension, arrhythmias, nausea, flushing and sweating until they were 
discharged from post anaesthesia care unit.
The results were analysed using student t –test, and a P value of less the 0.05 was 
taken significant.
With  patients  matched for  demographic  data  the  results  showed there  was  no 
significant difference in base line values between two groups. There was a reduction in 
the heart rate and mean arterial pressure in both groups but when both the groups were 
compared there was statistically  significant  reduction of heart  rate and mean arterial 
pressure  in  Magnesium  sulphate  group.  (P  <  0.05).  There  was  no  significant 
prolongation of Train of four values between the two groups, and there was no side 
effects observed in any of the patients in this study.
CONCLUSION
CONCLUSION
We conclude that, Magnesium sulphate in the dose of 30mg/kg given 
intravenously one minute prior to induction,
 Attenuates the cardiovascular responses to laryngoscopy and intubation in a better 
manner than lignocaine.
 Does not cause any adverse effects in any of the patients.
 Does not cause prolongation of the neuromuscular blockade.
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PROFORMA
PROFORMA
DEPARTMENT OF ANAESTHESIOLOGY 
THANJAVUR MEDICAL COLLEGE
Name & Address:                          Age/ Sex:             I.P. Number:
Assessment no. :                                                                     Unit:
Diagnosis:                                 Surgical procedure:                        
Anaesthesiologist:                                      Surgeon:                         
PREANAESTHETIC ASSESMENT:
History:                                             
CLINICAL EXAMINATION:     P.R.:           B.P:         Ht.:              Wt.:      
                                                      CVS:          RS:                   Airway:
ASA :                                                                                            
INVESTIGATIONS : Blood group:             Hb%:                     
                Urea                                Sugar                      ECG:
Blood                             Urine
                Sugar                           Albumin                     CXR:
PREMEDICATION: 
Sl.
No
:
DRUG DOSE ROUTE TIME
1.
PARAMETERS:
PARAMETERS
HEART 
RATE 
(min)
SYSTOLIC 
BP (mm 
Hg)
DIASTOLIC 
BP (mm Hg)
MAP 
(mm 
Hg)
BASELINE
POST INDUCTION
POST 
LARNYGSCOPY
POST 
INTUBATION(1min)
POST 
INTUBATION(3min) 
POST 
INTUBATION(5min)
TOF:
INTRAOPERATIVE COMPLICATIONS: 
PACU OBSERVATIONS:
MASTER CHART (LIGNOCAINE GROUP)
Sl. 
No. Name
Age/
Sex
Wt.
(kgs) Basal
Post induction Post 
laryngoscopy
Post 
intubation
(1 min)
Post 
intubation 
(3 min  ).
PR MAP PR MAP PR MAP PR MAP PR
1 Maniammal 18/F 52 85 95 80 88 84 90 84 94 82
2 Chellammal 22/F 54 90 112 84 108 88 110 90 114 86
3 Kalyani 25/F 50 88 106 80 98 86 100 89 105 86
4 Manjula 30/F 55 92 110 85 99 88 105 90 107 88
5 Murugan 35/M 48 75 99 68 95 74 100 75 100 74
6 Marimuthamml 40/F 58 82 85 76 80 79 84 80 84 78
7 Bharathiraja 42/M 60 85 79 78 75 80 78 84 78 82
8 Vembu 44/M 55 95 82 90 78 92 80 94 81 93
9 Janaki 40/F 52 92 94 88 89 92 92 94 94 93
10 Saraswathy 43/F 55 89 82 82 79 86 80 87 84 86
11 Suresh 42/M 55 90 92 84 88 85 90 88 92 86
12 Balakrishnan 38/M 50 88 95 80 90 85 92 88 92 86
13 Jayakumkumar 20/M 50 85 88 78 80 82 85 84 86 83
14 Subbaram 47/M 52 87 84 80 79 85 82 86 84 86
15 Radhakrishnan 38/M 54 88 80 80 72 85 78 87 79 86
16 Marimuthu 32/M 60 92 95 88 89 89 92 90 92 88
17 Vasantha 30/M 52 90 98 86 90 89 95 89 95 87
18 Revathi 22/F 50 85 89 78 85 82 88 83 88 80
19 Thangaraj 38/M 55 78 107 75 100 78 102 80 105 78
20 Murugesan 40/M 52 80 100 75 92 79 98 82 99 80
MASTER CHART (MAGNESIUM GROUP)
Sl. 
No. Name
Age/
Sex
Wt.
(kgs) Basal
Post induction Post 
laryngoscopy
Post 
intubation
(1 min)
Post 
intubation 
(3 min  ).
PR MAP PR MAP PR MAP PR MAP PR
1 Sanglimuthu 20/M 55 88 94 78 80 80 84 82 85 80
2 Natarajan 25/M 58 90 120 82 100 85 104 85 104 83
3 Balasundar 30/M 52 82 105 72 88 76 91 80 92 80
4 Kathiresan 35/M 54 86 90 78 64 80 86 81 87 80
5 Vasantha 40/F 60 82 82 70 69 74 72 75 74 73
6 Murugeswari 42/F 52 92 90 82 80 84 84 84 84 82
7 Kamala 18/F 52 88 88 72 83 76 85 76 86 73
8 Vasunathan 42/M 55 85 106 72 85 74 86 76 89 73
9 Manoharan 44/M 60 89 97 78 80 80 84 82 87 80
10 Latha 45/F 52 82 98 75 83 78 89 78 90 76
11 Devanai 47/F 55 86 90 78 80 72 84 74 86 72
12 Saraswathy 37/F 52 95 110 79 95 82 98 85 99 83
13 Kalaiselvi 38/F 54 90 96 75 80 78 82 80 84 78
14 Sathiakala 38/F 55 85 90 72 75 72 80 74 82 72
15 Suresh 37/M 50 80 82 72 69 74 72 75 74 73
16 Jeyakumar 35/M 48 96 88 82 82 84 84 84 86 82
17 Mathiventhan 32/M 40 92 97 80 80 83 83 85 85 83
18 Srirengam 28/F 50 90 96 75 80 79 82 80 85 78
19 Sambanthamoorthy 28/M 50 82 94 71 82 73 84 75 85 73
20 Rasiya 25/F 55 85 105 74 85 76 88 76 89 74
